Hwasun-gun Wins 'Best Brand Award' Selected by Consumers

Published 08 Mar.2022 14:57(KST)

[Hwasun=Asia Economy Honam Reporting Headquarters Reporter Kim Ji-woon] Jeonnam Hwasun-gun announced on the 8th that it won the Grand Prize in the Vaccine and Biopharmaceutical Industry Leading City category at the ‘2022 Consumer-Selected Best Brand Awards’ ceremony held in Seoul.

The county was recognized for its achievements in leading the national vaccine and biopharmaceutical industry by establishing a K-Global vaccine and bio hub centered on the only Hwasun Vaccine Industry Special Zone in Korea, and was selected as the Grand Prize winner in the Vaccine and Biopharmaceutical Industry Leading City category.

This is the third time winning the Grand Prize in the Vaccine and Biopharmaceutical Industry Leading category.

The 2022 Consumer-Selected Best Brand Awards were given after consumer research and expert evaluations to discover the best brands in each category.

Since being designated as Korea’s only vaccine industry special zone in 2010, the county has established a foundation that supports all stages of vaccine and biopharmaceutical development, including research and development, preclinical and clinical trials, commercialization, certification, and manufacturing, emerging as a K-Global vaccine hub.

Since the 7th local government administration, Hwasun has succeeded in attracting large-scale national support institutions in the vaccine and biopharmaceutical industry sector to the Hwasun Vaccine Special Zone and is actively discovering and promoting new national projects.

Representative projects include ▲National Vaccine Safety Technology Support Center (budget 28.3 billion KRW) ▲National Immunotherapy Platform (46 billion KRW) ▲m-RNA Vaccine Demonstration Support Infrastructure Construction (43 billion KRW) ▲Expansion of National Vaccine Safety Technology Support Center Functions (44.2 billion KRW) ▲Immunocellular Therapy Industrialization Technology Platform (20 billion KRW) ▲Biohealth Convergence Knowledge Industry Center Construction (32 billion KRW), among others.

The county has either started construction or plans to begin construction in the first half of this year for large-scale national projects in the vaccine and biopharmaceutical industry such as the National Vaccine Safety Technology Support Center, National Immunotherapy Innovation Platform, and Immunocellular Therapy Industrialization Technology Platform.

The National Vaccine Safety Technology Support Center within the Hwasun Vaccine Industry Special Zone was recently selected as a practical training center for the ‘WHO Global Bio Middle and Low-Income Countries Workforce Training Hub.’

A county official said, “We will accelerate the promotion of large-scale national projects in the vaccine and biopharmaceutical industry sector and strive to attract related companies to complete the blueprint of ‘Hwasun, the No.1 New Economy Zone.’ We will lead the government’s ‘K-Global Vaccine Hub Vision and Strategy’ project and take a step forward as a K-Global vaccine hub.”